Hobbs Eric's Form 4/A amendment
AmendedBruker Cellular Analysis, Inc. (CELL) · filed May 23, 2022
- Accession no.
- 0001567619-22-011566
- Filed
- May 23, 2022
- Trade date
- May 13, 2022
- Filing delay
- 10 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- May 13, 2022
This filing lists 1 non-derivative transaction. It carries over 6 transactions from the original filing that it did not restate. Open-market sales total $970.9K. It was filed 10 days after the trade.
This amendment restates part of 0001567619-22-010597 (filed May 13, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hobbs EricCIK 0001817415 | Officer (see Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 13, 2022 | Common Stock | SSaleDisposed | −6,198 | $4.97 | −$30,804.06 | 184,058 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001567619-22-010597 (filed May 13, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 11, 2022 | Common Stock | MOption exerciseAcquired | +1,302 | $0.64 | +$833.28 | 373,829 | Direct | |
| May 11, 2022 | Common Stock | MOption exerciseAcquired | +37,500 | $0.64 | +$24,000 | 411,329 | Direct | |
| May 11, 2022 | Common Stock | SSaleDisposed | −98,011 | $4.18F2 | −$409,685.98 | 313,318 | Direct | |
| May 12, 2022 | Common Stock | SSaleDisposed | −123,062 | $4.31F3 | −$530,397.22 | 190,256 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 11, 2022 | Common Stock | MOption exerciseDisposed | −1,302 | $0.00 | $0 | 0 | Direct | |
| May 11, 2022 | Common Stock | MOption exerciseDisposed | −37,500 | $0.00 | $0 | 0 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.66. The reporting person undertakes to provide Berkeley Lights, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.50. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2
On May 13, 2022, the reporting person filed a Form 4 reporting the sale of 7,531 shares of common stock at $4.97 per share pursuant to a Rule 10b5-1 trading plan. The total amount reported sold on May 13, 2022 was based on incorrect information provided by the reporting person's broker. The total number of shares sold on May 13, 2022 was 6,198, rather than 7,531.
Remarks
President - Antibody Therapeutics